A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

This is a study testing a new combination of three drugs (SHR-A2102, adebrelimab, and SHR-8068) for people with advanced non-small cell lung cancer (NSCLC) that cannot be surgically removed or has spread to other parts of the body. **You may be eligible if...** - You are between 18 and 70 years old - You have confirmed advanced or metastatic non-small cell lung cancer that cannot be surgically removed - You have at least one measurable tumor on imaging - Your general health score (ECOG) is 0 or 1 **You may NOT be eligible if...** - You have active or symptomatic brain metastases - You have previously been diagnosed with another cancer - You have significant fluid buildup in the abdomen, chest, or around the heart that cannot be controlled - You received any cancer treatment within 4 weeks before starting the study - You have uncontrolled tumor-related pain or severe heart or brain vascular disease Talk to your doctor to see if this trial is right for you.